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Abbreviations 
AR  acute rejection 
BAFF  B cell activating factor 
BR  borderline rejection 
cABMR chronic antibody mediated rejection 
CNS  central nervous system 
DC dendritic cell 
DcR3 decoy receptor 3 
dpi  days post inoculation 
FDC  follicular dendritic cell 
GN  glomerulonephritis 
HVEM herpes-virus entry mediator 
i.p.  intraperitoneally 
IgAN  immunoglobulin A nephritis 
LD50  median lethal dose 
LIGHT  LT-like exhibits inducible expression and competes with herpes simplex 
virus glycoprotein D for herpes-virus entry mediator 
LN  lupus nephritis 
LT  lymphotoxin 
LTβR  lymphotoxin beta receptor 
MBA  mouse bioassay 
MFGE8 milk fat globule-EGF factor 8 protein 
MHC  major histocompatibility complex 
NF-κB  nuclear factor kappa-light-chain enhancer of activated B cells 
NZB New Zealand black mouse 
NZBW New Zealand black x New Zealand white F1 generation 
NZW New Zealand white mouse 
PrP  prion protein 
PrPC  prion protein cellular = cellular prion protein 
PrPSc  prion protein scrapie = pathogenic (misfolded) form of the prion protein 
qRT-PCR quantitative reverse transcription polymerase chain reaction 
RIP  rat insulin promoter 
SLC  secondary lymphoid-organ chemokine 
SLO secondary lymphoid organs 
sLTβR soluble lymphotoxin beta receptor 
TEC  tubular epithelial cell 
TLO  tertiary lymphoid organs 
TLT   tertiary lymphoid tissue 
TNF(R) tumor necrosis factor (receptor) 
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1. Introduction 
Lymphotoxins (LTs) are cytokines, which belong to the TNF superfamily. Two distinct 
forms have been identified designated lymphotoxin  (LTα)1, 2 and lymphotoxin β 
(LTβ)3. They are part of a multifaceted signaling network4, 5. LTα exists as secreted 
homotrimer (LTα3) or in conjunction with LTβ as a membrane-anchored heterotrimer 
LTα1β2 or LTα2β1, the latter of which is less abundant3, 6. Ligands overlap in binding 
to three related receptors termed TNF receptor 1 (TNFR1), TNF receptor 2 (TNFR2) 
and the lymphotoxin β receptor (LTβR). LTα3 signals via TNFRs 1 (and 2)7, whereas 
LTα1β2 only binds to LTβR8. 
LIGHT (LT-like exhibits inducible expression and competes with herpes simplex virus 
glycoprotein D for herpes virus entry mediator) is another member of the TNF family9, 
10 and homologous to LTs11. It is membrane anchored and can bind to the LTβR12. 
Another receptor for LIGHT is HVEM (herpes-virus entry mediator), which is expressed 
on T cells13. Furthermore, LIGHT can also bind to Decoy receptor 3 (DcR3) (Figure 
1), which is a secreted receptor that blocks the biologic action of the ligands FasL and 
LIGHT14, 15 but can also activate T cells via binding to TL1A16. 
Activation of LTβR via LIGHT or LTα1β2 can activate the classical and alternative 
nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) pathway 
promoting inflammation, immune cell clustering and secondary lymphoid organ (SLO) 
formation4, 17 (Figure 1). LTβR is ubiquitously expressed in parenchymal cells (stromal 
fibroblasts, epithelial cells), follicular dendritic cells, endothelial cells (ECs) and cells of 
myeloid origin, but not by T, B or NK cells18-21. It is strongly expressed in the mouse 
kidney22. The LTα1β2-LTβR system controls the organogenesis and homeostasis of 
SLO4. The LTβR is involved in T cell costimulation and clonal expansion of T cells and 
important for maintenance and proliferation of dendritic cells (DCs)23-26. 
LT signaling plays a significant role in chronic inflammation27 and is important in the 
formation of tertiary lymphoid organs (TLOs)28-31 in a process termed lymphoid 
neogenesis27. In renal biopsies with chronic glomerulonephritis (GN) or interstitial 
nephritis, TLOs are detected in over 25% of biopsies and in renal allografts in up to 
50%32-34. LTα and LTβ are expressed on blood B, T and NK cells upon activation35, 36. 
Within lymphoid organs, LTs are constitutively expressed on lymphocytic cells and 
DCs, consistent with a maintenance function in these tissues37-39. Nonhematopoietic 
cells such as hepatocytes40, 41, glial cells42 and multinucleated giant cells also express 
LTα and β43. 
Experimental therapeutic strategies have been developed to interfere with LT 
signaling. Browning and colleagues have created a soluble LTβR-Ig (sLTβR-Ig) fusion 
protein, which blocks signaling of LTα1β2 and LIGHT44. Furthermore, an LT antibody 
has been created, which antagonizes LTα3 and LTα1β245. Blocking LT signaling using 
these approaches has been therapeutic in non-renal autoimmune inflammatory 
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conditions in animal models such as collagen-induced arthritis and experimental 
autoimmune encephalitis45, Sjoegren’s syndrome46, colitis47 and insulitis48. In 
experimental prion disease, treatment with sLTβR-Ig abolishes prion accumulation and 
replication in the spleen and retards neuroinvasion of the infectious agent49, 50. 
 
 
 
Figure 1. (A) Schematic representation of the receptors and ligands of the TNF/LT family. (B) 
Upon ligation of the LTβR, two NF-κB pathways can become activated. The canonical (left) 
results in initiation of IKKβ and RelA and stimulates expression of inflammatory genes like 
VCAM-1, CCL4, and CXCL2. Additionally, it triggers an increase of the NF-κB2/p100 precursor 
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protein. The alternative or non-canonical pathway (right) involves the stimulation of NIK, which 
activates IKKα to generate active p52, which together with RelB triggers the transcription of 
genes associated with organogenesis and homeostasis of SLOs and TLOs such as CXCL13, 
CCL19, BLC, CCL21, CXCL21 and BAFF (adapted from5, 17, 51). 
 
 
Even though LTs play an important role in chronic inflammation with or without 
formation of TLOs, barely any information is available concerning the LT system in 
kidney diseases. We therefore investigated renal LT expression in inflammatory kidney 
diseases such as IgA nephropathy, lupus nephritis and crescentic glomerulonephritis 
in humans. Furthermore, we examined the expression of LTs in human kidney biopsies 
with acute and chronic allograft rejection and in a rodent model of acute transplant 
rejection. To assess the functional role of LTs in kidney inflammation we studied the 
effects of LTβR signaling in renal cells in vitro and the impact of blocking the LTβ 
receptor in a rodent model of lupus nephritis. Since LTs had been shown to be 
important in peripheral prion propagation in SLOs we explored the impact of LT 
induced and spontaneous inflammation in the kidney and other parenchymal organs 
on peripheral prion pathogenesis in mice. 
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2. Summary of included publications 
2.1. Chronic lymphocytic inflammation specifies the organ tropism of prions52  
Chronic inflammatory conditions typically lead to infiltration of the affected tissue with 
inflammatory cells. Infiltrating cells may be diffusely scattered but can also form larger 
aggregates with lymphoid microarchitecture. These organized structures are called 
TLOs or tertiary lymphoid tissue (TLT)31. As described above, the LT system is 
important in TLO formation. Organized lymphoid infiltrates comprise T and B 
lymphocytes, follicular dendritic cells (FDCs), DCs, and macrophages32, 53-55. FDCs, B 
cells and other components of the immune system are also involved in prion 
propagation49, 56-60. Prions are proteinaceous infectious agents causing slowly 
developing fatal central nervous system (CNS) diseases called transmissible 
spongiform encephalopathies (TSEs)61 such as Creutzfeldt-Jakob disease in humans 
and scrapie in sheep. Prions are detectable in SLOs (i.e. spleens, lymph nodes, 
peyer’s patches) long before they invade the CNS and cause clinical symptoms62. Non-
neural and non-lymphoid tissues are usually devoid of prions. PrPSc is the misfolded 
disease associated isoform of the normal host prion protein (PrPC) and accumulates in 
the CNS and SLOs of affected animals61, 63, 64. As opposed to PrPC, PrPSc is insoluble 
in detergents and relatively resistant to digestion with proteases. Some researchers 
use the term PrPSc synonymous with prion infectivity61. Besides PrPC, replication of 
prions in SLOs necessitates follicular dendritic cells (FDCs). Maintenance of FDCs 
depends on LT α, β and TNF56-58, 65, 66. Inhibition of LT and TNF interferes with 
peripheral prion replication and neuroinvasion49, 67-69. We thus hypothesized that 
chronic inflammation with upregulation of LTs in non-lymphoid organs might influence 
prion pathogenesis. We scrutinized this question in transgenic and spontaneous 
mouse models of chronic inflammation, including nephritis, pancreatitis, and hepatitis. 
As a model for renal inflammation, we selected transgenic mice expressing LTα under 
the control of the rat insulin promoter (RIP) in pancreatic β islet cells and renal proximal 
tubules28, 70. These animals develop interstitial inflammatory follicles with features of 
TLOs in kidney and pancreatic islets. As an additional model for chronic renal 
inflammation, we chose NZB x NZW-F1 (NZBW) mice. Besides glomerulonephritis 
NZBW mice develop interstitial nephritis with distinct B and T cell areas, small FDC- 
clusters, and features indicative of functional germinal centers. Parental NZW mice are 
devoid of interstitial nephritis and were used as controls. We furthermore investigated 
mice expressing the secondary lymphoid organ chemokine (SLC = CCL21) under 
control of the RIP71. These mice (RIPSLC) contain follicles in the pancreas with 
organized T and B cell zones and FDC networks. As a chronic hepatitis model, we 
used bitransgenic mice expressing LTα and β in the liver under the control of the 
albumin promoter. Livers of AlbLTαβ mice have structured aggregates of inflammatory 
cells with features of TLOs. Quantitative RT-PCR (qRT-PCR) revealed that LTβ was 
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significantly upregulated not only in LT transgenic, but also in NZBW kidneys whereas 
RIPSLC mice had increased LTα expression in pancreas and kidney.  
AlbLTαβ, RIPLTα, NZBW, NZW, RIPSLC and control mice were inoculated 
intraperitoneally (i.p) with a dose of 5 log LD50 mouse scrapie prions (LD50 = median 
lethal dose) and sacrificed at various days post inoculation (dpi). PrPSc tissue loads 
were determined by Western blotting of organ homogenates after enrichment by 
phosphotungstate precipitation72, 73. We detected PrPSc at 60, 75, and 90 dpi in 
comparable amounts in all spleens of each genotype, but not in livers, kidneys, or 
pancreases of wild-type mice. At 75 dpi PrPSc immunoreactivity was detected in two 
out of three AlbLTαβ livers while RIPLTα kidneys and pancreases were negative. At 
90 dpi, PrPSc was present in all RIPLTα kidneys, RIPLTα pancreases, AlbLTαβ livers, 
and NZBW kidneys. With the exception of one RIPLTα kidney, which disclosed 
possible traces of PrPSc, control kidneys, pancreases and livers were negative. By 
histoblotting of tissue, we confirmed PrPSc deposits colocalizing with inflammatory 
infiltrates in inflamed organs.  
We then investigated whether inflammation influences the distribution of prion 
infectivity during the preclinical phase of infection. Tissue homogenates of prion 
inoculated mice were assayed at 60 dpi for prion infectivity by mouse bioassay (MBA; 
incubation time interval assay)74, 75. Spleens displayed comparably high titers of 4 - 6 
log LD50 prion infectivity per gram of tissue. Wild-type pancreata and kidneys lacked 
infectivity, whereas RIPLTα kidney and pancreas titers ranged between borderline (i.e. 
< 100% of indicator animals inoculated developed prion disease) and 1.4 log LD50/g. 
At 75 dpi, RIPLTα pancreas and kidney titers were 3.3 and 4 log LD50/g, whereas 
controls were noninfectious. At 90 dpi, all RIPSLC and RIPLTα pancreata and one 
RIPLTα kidney had prion titers approximating those of spleen, while controls displayed 
undetectable or borderline infectivity. NZBW kidneys contained prion titers of 2.5 to 3.5 
log LD50/g whereas controls were noninfectious. Infectivity of wild-type livers, kidneys, 
and AlbLTαβ kidneys was below detectability or borderline, while AlbLTαβ livers had 
titers of 3.1 to 3.4 logLD50/g 90 days dpi (Figure 2). 
LTα-/- and LTβR-/- knockout mice suffer from spontaneous structured lymphocytic 
infiltrations in liver, kidney, pancreas, lungs and other organs76-78. The inflammatory 
foci contain B, T and dendritic cells, but lack mature FDCs. Despite the severe 
inflammatory changes livers and kidneys of prion-inoculated LTα-/- and LTβR-/- mice 
were devoid of prion infectivity or PrPSC at 90 dpi. 
Taken together, this study was the first to indicate, that chronic follicular inflammation 
permits accumulation of prion infectivity in otherwise prion-free organs such as kidney, 
pancreas and liver. 
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Figure 2. Prion infectivity in organs with and without inflammation. Infectivity titers in 
organs of wild-type, RIPLTα, AlbLTαβ, RIPSLC, NZW and NZBW mice as quantified by 
transmission to indicator mice at 90 dpi. Each column demarcated by dashed lines indicates 
one mouse. Symbols underneath the dashed horizontal line designate attack rates of <100%. 
Apart from a RIPLTα kidney that caused an attack rate of 75%, RIPLTα and NZBW kidneys, 
RIPSLC and RIPLTα pancreases, and AlbLTαβ livers comprised prion infectivity with 
significant titers at 90 dpi. Wild-type kidneys, livers and pancreases and NZW kidneys 
contained borderline or undetectable prion infectivity (adapted from 52).  
 
 
2.2 Coincident scrapie infection and nephritis lead to urinary prion excretion79 
Above we established that interstitial inflammation with TLO like structures in the 
mouse kidney induced by ectopic expression of the cytokine LT enabled prion 
accumulation. Mice with lupus-like disease (NZBW mice) and organized inflammatory 
foci in the kidney (associated with upregulation of LTβ) also accumulated prions. In this 
study, we examined if prion infectivity is shed into the urine from kidneys replicating 
prions. 
First, we performed extensive histologic analysis to characterize the renal phenotype 
of several mouse models we intended to use to address this question. We revealed 
that the ectopic expression of LT in the kidney did not only lead to organized 
tubulointerstitial inflammation, but also resulted in a glomerular pathology. RIPLT 
mice suffer from an immune complex glomerulonephritis with mesangial proliferation 
and glomerular subendothelial immunoglobulin (Ig) and complement deposition. 
NZBW mice have severe crescentic GN associated with glomerular immune complex 
and complement deposition with prominent glomerular capillary sclerosis. MFGE8 
(milk fat globule-EGF factor 8 protein) knockout (-/-) mice80, which are inflicted with 
circulating antinuclear and anti-dsDNA antibodies, showed glomerular basement 
membrane thickening, mesangial and endocapillary hypercellularity, glomerular 
immune complex and complement depositions with mesangial and subendothelial 
deposits on electron microscopy (EM). NZW mice had a mild glomerular phenotype 
with few mesangial electron dense deposits on EM. Histology of C57BL/6 and 129Sv 
x C57BL/6 mice was unremarkable. Only RIPLT and NZBW mice exhibited organized 
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tubulointerstitial infiltrates (Figure 3). Compared to controls, NZBW, NZB and MFGE -
/- mice were strongly, whereas RIPLT and NZW only mildly proteinuric. 
 
Figure 3. Histopathology in RIPLTα, NZBW, MFG-E8-/- and control mice. H&E-stained 
paraffin sections of age-matched RIPLTα, C57BL/6, NZBW, NZW MFG-E8-/- and 129Sv x 
C57BL/6 kidneys. Renal lymphocytic infiltrates are present in RIPLTα and NZBW 
(arrowheads), but not in MFG-E8-/- kidneys or controls (NZW, C57BL/6, 129Sv x C57BL/6).  
 
To test if prion infectivity spills over from inflamed kidneys into urine, we administered 
prions i.p. to RIPLTα and NZBW mice. I.p. prion injected AlbLTαβ transgenic mice (no 
renal pathology), NZW, NZB, C57BL/6, tga20 transgenic mice (which overexpress 
PrPC approximately 20 fold74), MFG-E8 knockout80 mice and 129Sv × C57BL/6 served 
as controls since these mice do not develop interstitial nephritis. We collected urine 
from each genotype at various time points before the animals became symptomatic 
from prion disease and from terminally scrapie-sick mice. We intracerebrally inoculated 
purified urinary proteins pooled from groups of three to six mice into PrPC 
overexpressing tga20 mice, which served as indicator animals (Figure 4). We detected 
prion infectivity in urine of presymptomatic RIPLTα and NZBW as well as in scrapie-
sick RIPLTα mice. No prion infectivity was identified in any of the control animals at 
any time point after prion inoculation (Figure 5).  
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Figure 4. Transmission of prions through urine. Urine samples were collected from 
individual donors (horizontal lines) at time points after intraperitoneal prion inoculation, denoted 
by vertical lines, and pooled (intersections between lines, arrows). Squares represent 
individual tga20 mice inoculated i.c. with urinary proteins. White squares: no scrapie 
symptoms; red squares: histopathologically confirmed scrapie; green squares: positive PrPSc 
immunoblot. Numbers within squares: days to terminal disease. Clinical disease: red line. Prion 
incubation time is expressed in days. Asterisk: intercurrent death without clinical scrapie signs. 
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Figure 5. Prion infectivity in mouse urine as assessed by mouse bioassay. Prion 
infectivity was only detected in urine from animals, which were infected with prions and had 
follicular interstitial inflammation (18.2%) but not in urine from mice without kidney pathology 
or with isolated glomerulonephritis. 
 
 
Whereas RIPLTα and NZBW mice suffer from combined interstitial lymphofollicular 
inflammation and glomerulonephritis, MFGE8 -/-, NZW, and NZB mice display 
glomerulonephritis but lack interstitial inflammation. We conclude that prionuria 
necessitates intrarenal organized inflammatory foci but not isolated glomerulonephritis. 
How do prions enter the urine? Blood-borne prions may be excreted by a defective 
filtration apparatus upon extrarenal replication. Alternatively, prions may be formed 
locally and excreted during leukocyturia. Although prionemia occurs in many 
paradigms of peripheral prion pathogenesis81, 82, the latter hypothesis appears more 
likely, because prionuria in our study was invariably associated with local prion 
replication within kidneys. 
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2.3 The lymphotoxin β receptor is a therapeutic target in renal inflammation83 
Little data are available on the LT pathway in human kidney diseases. Tubulointerstitial 
lymphoid infiltrates are often present in chronic renal diseases. As the LT pathway is 
known to be involved in chronic inflammation and the formation of TLOs70, we 
hypothesized that LTβR signaling plays a role in human renal diseases. Thus, we 
evaluated the expression of LTs and LTβR in human renal biopsies, the effects of LTβR 
signaling in renal cells in vitro, and the effect of LTβR inhibition in a rodent lupus model. 
We considered the involvement of the LT pathway in settings both with and without 
TLO involvement.  
In GN, injury begins in the glomerular tuft and with progression, inflammation and 
fibrosis spreads to the tubulointerstitium. To define a potential role for LTβR signaling, 
we performed transcriptional profiling of glomerular and tubulointerstitial compartments 
from renal biopsies with lupus nephritis (LN) and immunoglobulin A nephropathy 
(IgAN) using cDNA microarrays. In both diseases, LTβ mRNA was significantly 
upregulated in the tubulointerstitium, as well as in glomeruli. LTβR and LTα were 
expressed and LTα mRNA levels correlated significantly with the expression of LTβ.  
LIGHT mRNA was also increased in glomeruli. Expression of several genes known to 
be regulated by LTβR signaling was increased, notably, the chemokines CXCL12, 
CCL19, and CCL21.  
mRNA expression of LTβ in renal biopsies was confirmed in a second cohort by qRT-
PCR. LTβ mRNA expression was significantly higher in the tubulointerstitium from 
patients with LN as compared with controls. The same was true in crescentic and IgA 
glomerulonephritis (Figure 6). In individuals with GN, LTβ protein was present on 
infiltrating inflammatory and renal tubular epithelial cells (TECs) of the proximal tubule. 
Parietal epithelial cells (PECs) and cells in crescents were sometimes positive for LTβ 
in proximity to the corresponding receptor. Nodular accumulations of infiltrating cells 
were present in 24% and these contained higher scores for LTβ-positive lymphocytes. 
The LTβ receptor was widely expressed by intrinsic renal cells. In glomeruli, LTβR 
protein and mRNA were present on parietal epithelial cells (PECs) and in the 
mesangium. Prominent expression was detected on cells in extracapillary 
proliferations in crescentic GN. TECs were commonly positive for the LTβR (Figure 6). 
In summary, the induction of LTβ in human renal biopsies occurred primarily in 
lymphocytes and to a lesser extent in TECs. The corresponding receptor was present 
mainly on intrinsic renal cells. 
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Figure 6. LTβ and LTβR in human renal biopsies with glomerulonephritis. (a) Expression 
of LTβ mRNAs were quantified by qRT-PCR in the tubulointerstitial compartment of renal 
biopsies from living donors (controls, Ctrl), and from patients with glomerulonephritis (*P < 
0.05). (b, c) Immunohistochemistry on sections from renal biopsies using a monoclonal 
antibody against LTβ. (b) A structured interstitial infiltrate. The majority of cells in this lymphoid 
aggregate is LTβ-positive. (c) Tubular epithelial cells positive for LTβ (arrow) in a biopsy with 
IgA nephritis. (d - f) LTβR mRNA was localized in renal biopsies by in situ hybridization. (d) 
LTβR mRNA expression in PECs (arrowheads) and glomerular cells in a biopsy from cGN. (e) 
In addition to glomerular cells and PECs (arrowheads) LTβR mRNA expression was detected 
in cells within crescents (arrows); (f) LTβR mRNA was abundant in tubular epithelial cells. 
(scale bar 10 µm in d, f; 100 µm in e); inserts illustrate original magnification x 60). cGN, 
crescentic GN; LTβ, lymphotoxin b; LTβR, lymphotoxin β receptor; RT-PCR, reverse 
transcription polymerase chain reaction, PEC, parietal epithelial cells. Scale bar 100 µm in b-
d, f, 50 µm in e (adapted from83). 
 
As LTs and the LTβR were present in human kidney diseases, we used human renal 
tubular (HK-2) and mesangial (HMC) cell lines to further characterize the induction of 
LTs and the response to various stimuli. By stimulation with TNF alone, or in 
combination with interferon (INF)  we observed a strong upregulation of LT and LTβ 
in both cell lines with different kinetics. The LTβR was strongly expressed in both cell 
lines. Upon stimulation with an agonistic LTβR antibody, the expression of several 
cytokines such as CCL2 (Figure 7), CCL5 and CXCL8 was induced in these cells. In 
primary mouse parietal epithelial cells (mPECs) a prominent increase in LTβ mRNA 
was detected after exposure to TNF. Stimulation with an agonistic LTβR antibody 
resulted in a strong CCL2 induction (Figure 7). These data illustrate that human TECs 
and mesangial cells as well as mouse primary parietal epithelial cells can express LTs 
upon exposure to TNF. Furthermore, signaling via LTβR can directly activate 
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chemokine expression in vitro, consistent with the potential for this pathway to promote 
renal inflammation.  
 
 
  
Figure 7. In vitro studies on human HK-2 cells (a-c) and mouse PECs (d-f) exposed to 
cytokines and a LTβR stimulating antibody. (a) HK-2 cells were exposed to cytokines IFN, 
IFNβ, and IFNγ, a combination of all 3 IFNs, IFNβγ (1000U/ml each), TNF (25 ng/ml), a 
combination of TNF and IFNγ, or to IL2 (5 ng/ml) for 12 hrs. LT (left) and LTβ (right) mRNAs 
were quantified by real-time RT-PCR. (b) FACS analysis for the detection of LTβR on HK-2 
cells (2nd: control with secondary antibody only, unstained: without antibodies). (c) HK-2 cells 
stimulated with an LTβR agonist. HK-2 cells were exposed to increasing concentrations of 
LTβR agonistic antibody (in mg/ml) or control IgG for 24 h. CCL2 was quantified by qRT-PCR 
(ctr: media control). (d – f) Activation of mouse primary PECs by cytokines and LTβR signaling. 
(d) PECs were exposed to medium (ctr), TNF (25 ng/ml), IFNγ (1000U/ml) or a combination 
of TNF and IFNγ. LTβ mRNA was quantified by qRT-PCR. (e) Expression of LTβR protein in 
PECs was confirmed by FACS analysis. (f) mPECs were exposed to increasing concentrations 
of LTβR agonist antibody, control IgG or medium. CCL2 protein quantified by ELISA 
demonstrates significant induction. IFN, interferon; IL, interleukin; LT, lymphotoxin; TNF, tumor 
necrosis factor; RT-PCR, reverse transcriptase polymerase chain reaction. FACS, 
fluorescence-activated cell sorting; LTβR, lymphotoxin β receptor. ELISA, enzyme-linked 
immunosorbent assay; PECs, parietal epithelial cells. (*P < 0.05, **P < 0.01, ***P < 0.001); 
(adapted from83). 
 
Finally, we tested the efficacy of blocking the LTβR pathway in an accelerated mouse 
model of lupus nephritis. LTβR-Ig binds to LTα1β2 and LIGHT, which inhibits their 
interaction with the LTβR. NZB × NZW F1 mice (BWF1) develop an immune-complex 
GN, which reflects many aspects of human lupus nephritis84, 85. Adenoviral delivery of 
IFNα (Ad-IFN) to BWF1 mice accelerates the development of renal disease, however 
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without formation of TLOs86 as compared to the non- accelerated BWF1 mice. 
Treatment with LTβR-Ig was started at different times after the initiating viral transfer, 
(0, 3, and 5 weeks). We performed detailed analysis on mice at 7 weeks, with treatment 
starting at 3 weeks. Expression of renal LTβ mRNA rose progressively from week 5 
(Figure 8). In situ hybridization demonstrated LTβ mRNA expression in glomeruli, focal 
interstitial infiltrates, and TECs at 7 weeks. The LTβR was widely expressed in PECs, 
cells of the glomerular tuft, and tubular epithelial cells. LTβR-Ig treatment strongly 
reduced proteinuria and improved blood urea nitrogen at week 7. Histology of the 
glomeruli revealed less glomerular cellularity and matrix deposition with LTβR-Ig 
treatment and less tubulointerstitial inflammation (Figure 8). Neither IgM nor pan IgG 
anti-dsDNA antibody titers were reduced by LTβR-Ig treatment nor did it alter 
glomerular immune complex deposition. The chemokine genes CCL2, CCL20, and 
CXCL10 were downregulated upon LTβR-Ig treatment. Interleukin-6, which has been 
shown to correlate with lupus disease activity87, correlated with proteinuria and was 
significantly reduced by LTβR-Ig treatment. Taken together, LTβ and LTβR are 
expressed in BWF1 mice consistent with the pattern presented for human glomerular 
diseases. LTβR-Ig treatment for 4 weeks protected mice from renal damage and 
improved renal function at a stage after disease initiation. Treatment was associated 
with the downregulation of major cytokines and chemokines, such as CCL2 but 
independent of immune complex deposition. Our data suggest that blocking LTβR 
signaling in this lupus model decreases chemokine and cytokine release from renal 
cells resulting in reduced proliferation of glomerular as well as a diminished influx of 
inflammatory cells from the blood thereby reducing renal damage. 
In summary, we found that LT ligands are expressed in renal cells in vitro, in vivo, and 
in human renal biopsies. Renal cells can respond to LTβR activation with the potential 
to promote and amplify inflammation. Our data provides the first in vivo evidence for a 
role of LTβR signaling in lupus nephritis.  
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Figure 8. Treatment with LTβR-Ig reduces renal disease in the adenoviral-IFN 
accelerated BWF1 model. (a) An outline showing dosing regimens with arrows indicating the 
onset of drug treatments (mice treated between week 3 and 7 are illustrated in b-d). (b) 
Expression of renal LTβ mRNA measured by qRT-PCR illustrates a progressive increase after 
5 weeks. (c) A significant reduction in urinary protein and BUN was detectable. Total urinary 
protein and BUN prior to infection with the adenovirus (Pre-IFNa) or 7 weeks after infection 
with no treatment (IFN only), with a control antibody treatment (IFN+control Ig) or with 
prophylactic LTβR-Ig treatment (IFN+LTβR-Ig). Box and whisker presentation of the data 
(arms 10%–90% range) is shown with each circle representing one animal. Mann-Whitney 
comparison of control-Ig– and LTβR-Ig–treated groups was significant (P < 0.0001). (d) 
Treatment with LTβR-Ig resulted in a significant improvement of glomerular injury (periodic 
acid-Schiff stains, scale bars = 100 mm). Ad-GFP, Adenovirus green fluorescent protein 
(control adenovirus); Ad-IFN, adenovirus-interferon; BUN, blood urea nitrogen; IFN, interferon; 
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LTβ, lymphotoxin b; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction. 
(***P < 0.001); (adapted from 83). 
 
2.4 Lymphotoxin expression in human and murine renal allografts88 
Acute and chronic renal rejection are inflammatory processes and in renal allograft 
biopsies TLOs are present in up to 50%32-34. Even though early studies have provided 
evidence for the expression of LTβ in rejected rat and human renal allografts89, 90, a 
comprehensive investigation of LT expression in renal transplants has not been 
undertaken. Therefore, we examined the differential regulation of components of the 
LT system in human renal allograft biopsies and a murine model of renal 
transplantation. 
cDNA microarray analysis of human kidney allografts demonstrated robust 
upregulation of LTβ, LIGHT and one of its receptors, HVEM, as well as TNF receptors 
1 and 2 mRNA in kidneys with acute rejection (AR) compared to controls. Interestingly, 
in chronic allograft injury/IFTA (interstitial fibrosis/tubular atrophy) we observed a 
similar pattern. The upregulation of transcripts controlled by the alternative NF-κB 
signaling pathway, such as CXCL12, CXCL13, CCL19 and BAFF (B cell activating 
factor) in AR and IFTA strongly suggested activation of the LTα1β2-LTβR or LIGHT-
LTβR axis since aside from CD40L-CD40 interaction and BAFF91-94, LTβR activation 
is one of three major inducers of the alternate NF-κB pathway95. CD40L was neither 
upregulated in AR nor chronic allograft nephropathy and therefore unlikely to be solely 
responsible for the alternate NF-κB pathway triggering in this context. LTα and TNFα 
mRNAs were not significantly increased in the transcriptome of grafts with AR and 
IFTA compared to nephrectomy controls, which was unexpected, since activated 
lymphocytes as well as resident dendritic cells, have been shown to express these 
cytokines. LTβR mRNA did not show any differential regulation. This is in line with the 
previously described constitutive expression of the receptor in parenchymal cells and 
its promotor region suggesting a house keeping function96. 
In an independent set of 49 allograft biopsies analyzed by qRT-PCR, we detected 
robust upregulation of LTβ, and LIGHT in borderline rejection and AR. In addition, LT 
mRNA was upregulated. In allografts with IFTA, we also noticed a trend towards higher 
expression of LTα, β and LIGHT, which, however, did not reach statistical significance. 
Concordant with the above findings, LTβR was not differentially regulated (Figure 9). 
Interestingly, also the decoy receptor 3 (DcR3) mRNA was significantly upregulated in 
AR. DcR3 is a secreted decoy receptor which binds to and blocks the biologic action 
of the ligands FasL and LIGHT14, 15, 97, 98 but can also activate T cells via binding to 
TL1A16. It was recently shown to have negative prognostic value in patients with 
chronic kidney disease99. Whether DcR3 is a predictor of negative outcome also in 
renal transplant patients needs to be determined. There was no significant expression 
difference between borderline rejection and AR with respect to the transcripts 
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investigated. This could indicate that despite a morphologic difference on the light 
microscopic level acute and borderline rejection share features on the transcriptional 
level. Another possible explanation is that some of the cases diagnosed with borderline 
rejection might in fact have been cases of acute rejection. In our study, most of the 
cytokine mRNA levels in the different subgroups (borderline, AR and IFTA) did not 
significantly correlate with the degree of histopathological changes in the different renal 
compartments. This is in line with previous studies, which demonstrated that 
transcriptional upregulation of inflammatory or injury associated genes do not correlate 
well with morphological changes in transplant biopsies but often predict the outcome 
better than the histology100, 101. 
In a further experimental paradigm, mRNA expression patterns of members of the LT 
family and structurally related genes were assessed using cDNA arrays in patients with 
another chronic renal allograft injury termed transplant glomerulopathy (TG). 
Clustering analysis showed two distinct expression patterns. One cluster displayed 
strong upregulation of LTα, TNF, LIGHT, HVEM, BTLA, CXCL13, CCR7 and CCL21 
(cluster 1), whereas the second pattern (cluster 2) was characterized by increased 
expression of the LTβR, LTβ, TNF receptors 1 and 2, MADCAM and TROY. The 
segregation of these two clusters could reflect different progression stages of TG or 
distinctive underlying pathologies characterized by engagement of a different subset 
of components of the LT and TNF system resulting in a similar histopathologic pattern. 
The clusters might also reflect different stages of chronic interstitial inflammation with 
formation of ectopic lymphoid follicles. 
To investigate the expression of LTβ on the protein level, we performed 
immunohistochemistry on allograft biopsies. The analysis exhibited LTβ 
immunoreactivity in inflammatory cells and tubular epithelial cells (TECs) in biopsies 
with AR and IFTA (Figure 9). In implant biopsies, we rarely observed LTβ 
immunoreactivity. As in kidneys with various forms of GN (see 2.3), we observed 
expression of LTβ on infiltrating mononuclear inflammatory cells diffusely within the 
tissue or in follicular infiltrates. The observed upregulation of LTβ in TECs suggests 
that tubular damage or TEC activation by cytokines from infiltrating cells leads to 
upregulation and release of LTβ, which may activate the LTβR on neighboring TECs 
and/or local immune cells such as DCs, modulating the inflammatory response. That 
TECs serve as regulatory cells in acute rejection – either amplifying or ameliorating 
inflammation – has been shown in previous studies102. Interestingly, we did not observe 
tubular expression of LTβ in implant biopsies. This indicates that even a severe 
ischemic stimulus (cold and warm ischemia) does not suffice to induce LTβ expression 
in TECs.  
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Figure 9. Expression of LTs in human renal allografts. (a) Upregulation of LT mRNAs in 
human renal allograft biopsies compared to biopsies from living donors. LTα, LTβ, LTβ 
receptor, DcR3 and LIGHT mRNA expression was quantified by qRT-PCR. Control biopsies 
were taken from living donors (LD) before implantation (displayed are mean scores + SEM). 
(b) Semiquantitative expression of LTβ in human allograft biopsies. LTβ immunohistochemistry 
was performed in biopsies with AR, IFTA and controls (ctrl). Upper panel shows 
semiquantitative analysis of LTβ positivity in tubular epithelial cells (TECs; left), LTβ positivity 
in infiltrating inflammatory cells in follicular infiltrates (middle) and LTβ positivity in diffusely 
infiltrating inflammatory cells (right). The lower panel shows examples of LTβ positivity in TECs 
(left; arrow depicts positively stained tubular epithelial cell), follicular infiltrates (middle; arrow 
depicts follicular infiltrate) and diffusely infiltrating cells (right) (scale bar = 50 µM). BR 
borderline rejection, AR acute rejection, IFTA interstitial fibrosis/tubular atrophy, LTβ, 
lymphotoxin β; LTβR lymphotoxin β receptor; TNFR, tumor necrosis factor receptor (* p< 0.05; 
**p < 0.01, *** p<0.001); (adapted from88). 
 
To explore the expression of LTs in renal transplants in another species we employed 
a model of acute renal allograft rejection using two fully MHC mismatched mouse 
strains103. In this model, we recapitulated our findings from human biopsy studies. 
Seven days after orthotopic renal grafting without immunosuppressive treatment 
histology of allografts showed severe acute tubulointerstitial rejection with interstitial 
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edema, diffuse inflammatory infiltrates, tubulitis and signs of acute tubular injury. qRT-
PCR displayed significant induction of LTα, LTβ, HVEM and LIGHT mRNAs. Again 
LTβR was not differentially expressed (Figure 10). These findings indicate that with 
respect to the LT system, mice react in a similar fashion as humans to engraftment 
with a foreign kidney. Given the ample disparities between the human and mouse 
immune system, this finding is critical regarding the translatability of results from 
studies in renal transplantation using this model system.  
To summarize, our study demonstrates for the first time, that essentially all 
components of the LT system are expressed and a subset of them strongly upregulated 
in rejected human renal allografts and in the acutely rejected mouse kidney. We 
therefore provide evidence for the involvement of the LT system in acute kidney 
rejection and chronic allograft injury.  
 
Figure 10. Lymphotoxin mRNA expression in mouse renal allografts. (A) Kidneys were 
transplanted from C57BL/6 into CBA mice (fully MHC mismatched allografts) or into C57BL/6 
(isografts). Kidneys were removed after seven days without any immunosuppressive 
treatment. (B) Mean fold-induction of LTα, LTβ, LTβ receptor, HVEM and LIGHT mRNAs 
quantified by quantitative RT-PCR for allografts compared to isografts seven days post 
transplantation. A very significant induction was found for LTα, LTβ, HVEM, LIGHT. (* p< 0.05, 
** p < 0.01, *** p<0.001, ns = non significant.) 
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3. Conclusion and Outlook 
Taken together, the first part of the work described above (2.1 and 2.2) demonstrated 
that chronic inflammation with TLO like structures permits accumulation of prion 
infectivity in normally prion-free organs. Tissue-specific expression of the 
proinflammatory cytokine (LTα) or chemokine (SLC) resulted in the establishment of 
new prion reservoirs. LTs therefore seem to play a major role in prion replication not 
only in SLOs, but also in TLOs. Furthermore, we found that inflamed kidneys of prion 
infected animals elicited prionuria. Our study was the first in the literature to prove that 
prion infectivity can occur in urine of animals with prion disease.  
What is the relevance of these findings? Knowing the tissue distribution of prion 
infectivity within infected individuals is crucial for the prevention of iatrogenic spread of 
prion diseases. In addition, there are important implications for the food industry and 
consumer protection with respect to transmission of bovine spongiform 
encephalopathy. Up to the point of our study, the risk of transmitting TSEs from tissues 
other than central/peripheral nervous system, lymphatic or intestinal tissues has been 
considered small104. However, our data suggest that extraneural and non-lymphoid 
tissues might gain the ability to accumulate or replicate prion infectivity if they are 
affected by chronic inflammatory conditions. Our findings furthermore indicate, that 
urine of individuals with prion disease such as CJD has to be considered potentially 
contagious. Prions excreted via urine could lead to prion contamination of the soil. 
Inflammation-associated prionuria may contribute to TSE transmission among sheep 
and free ranging deer and elk.  
Interestingly, a subsequent study demonstrated, that in sheep with concomitant 
scrapie infection and chronic lymphocytic mastitis, accumulation of PrPSc occurred in 
inflammatory follicles in mammary glands105. Mothers with mastitis and scrapie passed 
the disease on via milk to most of the suckling lambs106. Another successive study 
reported prion infectivity in urine from free ranging deer with chronic wasting disease 
(a prion disease affecting cervids). Lymphocytic inflammation was detected in the 
kidneys in 4/5 animals with infectious urine107. 
Our further studies on inflammatory kidney diseases and renal allograft rejection (2.3 
and 2.4) suggest that LTs may be important players in these conditions. We 
demonstrated, that LTβ is not only expressed by infiltrating cells, but also by intrinsic 
renal cells such as tubular epithelial cells. Our experiments in cultured immortalized 
and primary renal cells indicate that LTβR signaling appears to be a new pathway for 
the activation of renal cells and amplification of inflammation within the kidney. Since 
the lupus model we used did not involve TLOs, yet LTβR blockade still alleviated 
disease, interfering with LT signaling might be helpful in renal inflammatory conditions 
with and without TLO formation. Because in humans with lupus nephritis the disease 
is resistant to current immunosuppressive therapy in 20% to 70% of affected 
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individuals108, novel therapies are urgently needed. We think that blocking LTβR 
signaling could be a promising therapeutic approach in human lupus nephritis, but also 
other forms of chronic renal inflammation such as IgA nephropathy or crescentic 
glomerulonephritis. 
From our data, we cannot deduce which components of the LT system serve as 
positive or negative regulators in renal inflammation. Whereas inhibition of LTβR 
signaling seems to be beneficial in lupus nephritis, the role of LTs in allograft rejection 
is unclear. On the one hand, interfering with the LT system could be beneficial. In 
murine antibody mediated cardiac allograft rejection, blocking of the LTβR resulted in 
complete abrogation of TLO formation and prevented rejection109. Conversely, LTβR 
blockade in another model broke tolerance and caused inflammation and fibrosis of 
cardiac allografts110. We reason that LTβR blockade has the potential to be beneficial 
especially in chronic antibody mediated rejection (cABMR), for which efficient 
treatments are lacking111. An interesting study by Thaunat and colleagues examined 
explanted allografts of patients suffering from cABMR who had received B cell 
depleting therapy (rituximab). Despite complete absence of circulating B cells TLOs 
were detected within the graft with B cells persistently producing alloantibodies112. 
Given the capacity of LTβR blockade to abrogate TLOs109 we plan to examine the 
therapeutic potential of blocking LT signaling in a mouse model of cABMR with intra-
graft TLO formation113. However, as demonstrated above in the IFN–accelerated 
BWF1 lupus mouse, LTβR blockade can also alleviate renal inflammation without TLO 
formation. Therefore, we intend to investigate LTβR blockade using sLTβR-Ig and a 
LT neutralizing antibody in our model of acute murine allograft rejection. Several 
available (conditional) knockout models for various components of the LT system will 
aid us in dissecting the exact contribution of the LT system to renal allograft rejection. 
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